Haleon expects slower growth in 2026 amid cooling demand in the United States
The Sensodyne maker expects organic revenue to rise between 3% and 5% this year due to low consumer confidence. Cost cuts will help fund a share buyback.
Insights:
Haleon plc has forecast 2026 organic revenue growth of 3% to 5%, a range that falls below its medium-term target and trails market expectations of 4.4% according to a company-compiled poll. The announcement, made on February 25, 2026, signals a period of slower top-line growth for the major consumer healthcare company as it navigates shifting market conditions and adjusts its financial strategy to protect profit margins.
Management cited weak consumer demand in the United States 
US and softer sales within its respiratory health business as the primary drivers behind the revised guidance. This trend has impacted performance across key segments, including the Sensodyne brand and the Smokers' Health range. Brian McNamara noted that these headwinds necessitated a robust response to maintain investor confidence and support the firm’s financial health.
US and softer sales within its respiratory health business as the primary drivers behind the revised guidance. This trend has impacted performance across key segments, including the Sensodyne brand and the Smokers' Health range. Brian McNamara noted that these headwinds necessitated a robust response to maintain investor confidence and support the firm’s financial health.
